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Abstract
Human parvovirus B19 (B19V) causes a variety of human diseases. Disease outcomes of bone marrow failure in patients with
high turnover of red blood cells and immunocompromised conditions, and fetal hydrops in pregnant women are resulted
from the targeting and destruction of specifically erythroid progenitors of the human bone marrow by B19V. Although the
ex vivo expanded erythroid progenitor cells recently used for studies of B19V infection are highly permissive, they produce
progeny viruses inefficiently. In the current study, we aimed to identify the mechanism that underlies productive B19V
infection of erythroid progenitor cells cultured in a physiologically relevant environment. Here, we demonstrate an effective
reverse genetic system of B19V, and that B19V infection of ex vivo expanded erythroid progenitor cells at 1% O2 (hypoxia)
produces progeny viruses continuously and efficiently at a level of approximately 10 times higher than that seen in the
context of normoxia. With regard to mechanism, we show that hypoxia promotes replication of the B19V genome within
the nucleus, and that this is independent of the canonical PHD/HIFa pathway, but dependent on STAT5A and MEK/ERK
signaling. We further show that simultaneous upregulation of STAT5A signaling and down-regulation of MEK/ERK signaling
boosts the level of B19V infection in erythroid progenitor cells under normoxia to that in cells under hypoxia. We conclude
that B19V infection of ex vivo expanded erythroid progenitor cells at hypoxia closely mimics native infection of erythroid
progenitors in human bone marrow, maintains erythroid progenitors at a stage conducive to efficient production of
progeny viruses, and is regulated by the STAT5A and MEK/ERK pathways.
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Introduction
Human parvovirus B19 (B19V) is the only parvovirus so far
confirmed to be pathogenic to humans [1]. Infection by this virus is
the cause of the highly contagious ‘‘fifth disease’’ in children. It can
also result in serious, and occasionally fatal, hematologic diseases in
susceptible patients. Acute B19V infection can cause transient
aplasticcrisisinpatients with highlevelsofredbloodcelldestruction
and erythrocyte turnover (e.g., sickle-cell disease patients). Pure red-
cell aplasia and chronic anemia can also be a manifestation of
persistent B19V infection in immunocompromised patients [2].
Finally, aplastic crisis in the fetus and hydrops fetalis can occur as a
result of infection-induced anemia in pregnant women [3].
B19V belongs to the genus Erythrovirus of the Parvoviridae family
[4]. Infection by B19V is restricted exclusively to human erythroid
progenitor cells (EPCs) at the stage from the late burst-forming
unit-erythroid (BFU-E) to colony-forming unit-erythroid (CFU-E)
[2,5]. The 5.6-kb linear single-stranded DNA genome (ssDNA),
which is flanked by two identical terminal hairpin repeats, encodes
nonstructural proteins (NS1, 11 kDa and 7.5 kDa) and two capsid
proteins (VP1 and VP2) [6,7]. A model of ‘‘rolling hairpin’’-
dependent DNA replication of B19V has been proposed [8].
However, neither the mechanism underlying the unique tropism
of B19V genome replication in human EPCs, nor the cellular
factors involved, have been identified.
Currently, the study of B19V infection is hampered by the lack of
both suitable animal models and an efficient and productive in vitro
B19V propagation system. Attempts have been made to use in vitro
cultures of human bone marrow cells [9], megakaryoblastoid cells (the
UT7/Epo cell line [10] and its subclone UT7/Epo-S1 [11]), and
erythroid leukemia cells (the KU812Ep6 cell line [12]). However, all of
these are merely semi-permissive to B19V infection, producing only
low levels of viral proteins and viral genomes [13,14]. Recently, ex vivo
expanded primary human EPCs infected with B19V [15–17] have
shown extraordinary promise as an alternative system, based on high
expression of B19V capsid and non-structural proteins. Nevertheless,
these expanded EPCs failed to produce infectious virus at levels
sufficient to maintain the virus titer, and thus do not constitute a
productive culture system. Notably, B19V infection of primary EPCs at
low oxygen (1% O2, hypoxia) has been shown to promote B19V
infection, an effect that has been proposed to be as an outcome of
enhanced stimulation of the P6 promoter by HIF1a [18], a key
transcription factor that is stabilized in the context of hypoxia [19].
The extreme tropism of B19V for human erythroid progenitors
of the bone marrow and the high viremia [up to 3610
13 genomic
copies per ml of plasma [13]] characteristic of B19V-infected
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its co-receptors (CD49e and KU80) [21,22] have been invoked
based on their involvement in virus entry, but only partially
account for B19V tropism [23,24]. Erythropoietin (Epo) is another
candidate, as it is required for the maintenance and permissiveness
of human EPCs to B19V infection [10–12,16]. Using ex vivo
expanded EPCs, we recently demonstrated that signaling by Epo
and the Epo receptor (EpoR) serves as a molecular switch for
B19V DNA replication in cells which have internalized the virus
[24]. However, how Epo/EpoR signaling influences B19V
replication and which downstream molecules facilitate viral
DNA replication have not been understood. The EpoR signaling
pathway is triggered by ligation of Epo to EpoR, which activates
Janus kinase 2 (Jak2) such that it phosphorylates both itself and
EpoR at multiple tyrosine sites [25]. This initiates a kinase cascade
with three major branches, starting at the signal transducer and
activator of transcription 5A (STAT5A), mitogen-activated protein
kinase (ERK/MAPK) kinase (MEK) and phosphatidylinositol-3
kinase (PI3K). The balance of these three signaling pathways
directs the differentiation and proliferation of erythroid progen-
itors to erythrocytes.
In the present study, we report that ex vivo expanded CD36
+
EPCs cultured in the context of hypoxia support sustained
productive B19V infection, efficiently amplifying the numbers of
infectious virions within the cell by enhancing the level of viral
DNA replication. Our results reveal that STAT5A is critical in
promoting hypoxia-facilitated B19V infection in CD36
+ EPCs
during erythropoiesis, whereas MEK negatively regulates B19V
infection.
Results
Hypoxia promotes productive and sustainable B19V
infection of CD36
+ EPCs
To best mimic the bone marrow microenvironment in which
EPCs are found in vivo, we cultured a day 4 stock of CD34
+
hematopoietic stem cells (HSCs), that has been cultured under
normoxia from day 0 for a further 4 days under either normoxia
(21% O2) or hypoxia (1% O2). The day 8 CD36
+ EPCs produced
under the two conditions were confirmed to be nearly identical
with respect to the profiles of the major cell surface erythroid
markers (CD36, CD71 and CD235a) [24], the B19V receptor
(Globoside) [20] and the B19V co-receptors (CD49e and KU80)
[21,22] (Figure 1A). The absence of both CD34 (hematopoietic
maker) and CD41 (megakaryoblastic maker), and the nearly
complete expression of CD36, CD71 (Transferrin receptor) and
CD235a (Glycophorin A), on the cell surface under each condition
indicates that both sets of CD36
+ EPCs produced fall into a range
of late BFU-E to CFU-E progenitors (Figure 1A). Moreover, the
levels of B19V receptor and co-receptors on the cell surface were
similar on CD36
+ EPCs cultured under the two conditions.
We next infected both sets of CD36
+ EPCs with B19V at a
multiplicity of infection (MOI) of 5,000 genome copies (gc)/cell. At
48 hrs postinfection (p.i.), the virus-encoded nonstructural proteins
NS1 and 11 kDa were detected in more than 70% of infected cells
that had been cultured under hypoxia, but in fewer than 25% of
infected cells that had been cultured under normoxia (Figure 1B).
Consistent with this finding, the level of VP2-encoding mRNA in
infected cells cultured under hypoxia was 10 times greater than
that detected in the cells cultured under normoxia (Figure 1C).
Similar results were obtained when the B19V infection of day 8
CD36
+ EPCs that had been cultured under hypoxia starting at day
0 was examined (data not shown). The CD36
+ EPCs that were
switched to hypoxia at day 4 of culture were therefore used for the
remainder of this study. Additionally, the efficiency of the B19V
infection of the B19V semi-permissive UT7/Epo-S1 cells also
increased drastically under hypoxia (Figure S1A).
In order to examine the productivity and sustainability of B19V
infection of CD36
+ EPCs under hypoxia, we passaged B19V
preparations harvested from the initial infections under both
hypoxia and normoxia, through CD36
+ EPCs cultured under each
condition. Our results showed that, at the same MOI, B19V
infection generated approximately (,)5 times more capsid-
expressing cells among cells infected in the context of hypoxia
than in those infected in the context of normoxia (Passage 1)
(Figure 2A). Surprisingly, when cells were maintained under
hypoxia, the number of capsid-expressing cells increased as the
virus was passaged, reaching a rate of ,75% infection by the fifth
passage. In contrast, when the cells were maintained under
normoxia, the number of capsid-expressing cells decreased, with
fewer than 5% positive for capsid protein by the fifth passage
(Figure 2B). This difference was consistent with the progeny virus
yields under the two conditions, as assessed by titration of
infectious units (ffu) and virus particles (gc) (Figure 2C&D,
respectively). Specifically, at the fifth passage, a virus yield of over
90 ffu/ml was obtained from infected cells cultured under hypoxia,
whereas a yield of less than 5 ffu/ml was obtained from infected
cells cultured under normoxia. These results demonstrate that
B19V infection of CD36
+ EPCs under hypoxia leads to a
sustainable ‘‘productive infection,’’ and that in contrast, B19V
infection of cells under normoxia leads to only ‘‘permissive
infection,’’ with inefficient production of progeny virus resulting in
aborted infection after several passages.
Hypoxia facilitates B19V DNA replication, but not virus
entry or intracellular trafficking
We next examined which step during the virus life cycle is
facilitated in B19V-infected CD36
+ EPCs cultured under hypoxia.
To this end, we infected CD36
+ EPCs with B19V under each
condition. At 2 hrs p.i, we observed an equivalent level of virus
bound to the cells under the two conditions (Figure 3A, compare
lanes 1 and 2). However, at 24 hrs p.i., we detected an ,5-fold
increase in both the replicative form of double-stranded DNA (RF
DNA) and the single stranded DNA (ssDNA) genome in B19V-
infeceted CD36
+ EPCs under hypoxia (Figure 3A&B, 24 hrs). At
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Human parvovirus B19 (B19V) is the etiological agent of
fifth disease seen in children, aplastic crisis in sickle cell
disease patients, chronic anemia in immunocompromised
patients, and hydrops fetalis in pregnant women. After
more than 35 years since its discovery, B19V was still
unable to be propagated in vitro in a productive and
sustainable manner, which directly delayed the progress of
B19V pathogenesis study and consequently finding ways
to treat patients infected with B19V. We cultured human
erythroid progenitor cells at a hypoxic condition by
mimicking the natural niches of human bone marrow.
Our current work reveals, for the first time, a long-term
B19V infection of ex vivo expanded erythroid progenitor
cells at hypoxia. Thus, this finding will largely facilitate the
study of the mechanisms underlying B19V infection and
more importantly identification of approaches to treat
B19V infection. Finally, the identification of the cellular
signaling pathways in regulating B19V replication sheds
light on the virus-host interaction and will nominate
potential candidates for anti-virus drug targeting.
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fold increase of the ssDNA viral genome were observed in the cells
cultured under hypoxia (Figure 3A&B, 48 hrs). Notably, the ratio
of B19V ssDNA to RF DNA did not differ significantly in the two
groups of infected cells (,1:1; Figure 3A, lanes 5 and 6). These
results suggest that hypoxia promotes replication of the B19V
DNA as well as production of B19V progeny viruses (by ,20-fold
in the level of ssDNA viral genome).
This notion was confirmed by a careful assessment of virus entry
by a qPCR-based B19V DNA replication assay (Figure 3C), in
which cells at 2 hrs p.i. were pretreated with trypsin to remove
attached virion, and the number of viral genomes within the cells
was quantified. No significant difference in virus entry was
observed for CD36
+ EPCs cultured under normoxia vs. hypoxia,
suggesting that hypoxia does not affect viral entry. This result is
consistent with the fact that hypoxia did not affect the levels of the
B19V receptor and co-receptors on cell surface (Figure 1A). In
spite of the equivalent numbers observed for virus entry at 2 hrs
p.i., the number of B19V genome copies at 48 hrs p.i., was
increased by 2,382-fold in B19V-infected CD36
+ EPCs cultured
under hypoxia but only 101-fold in the cells cultured under
normoxia, thus replication of the B19V DNA is 20-fold more
efficient in cells cultured under hypoxia than in cells cultured
under normoxia (Figure 3C).
To rule out the possibility that the enhanced viral DNA
replication in CD36
+ EPCs cultured under hypoxia was due to an
increase in intracellular virus trafficking after virus had entered the
cell, we examined number of viral genomes in the nucleus during
early infection. As shown in Figure 3D, at 2 hrs p.i. the level of
viral genomes in the nucleus was next to undetectable in both sets
of CD36
+ EPCs. Viral genome accumulation began abruptly at
4 hrs p.i., and decreased gradually until 8 hrs p.i., presumably as
the result of virus clearance by the host. Interestingly, the viral
genomes in nuclei increased again sharply from 8 to 10 hrs p.i.,
indicating replication of the viral genome. Dramatic differences in
the number of the viral genomes in the nuclear fractions from
normoxia- and hypoxia-cultured EPCs were not observed until
after 12 hrs p.i., at which point the levels of the viral genome in the
nuclei of hypoxia-cultured CD36
+ EPCs began to rise relative to
those in normoxia-cultured CD36
+ EPCs, reaching a level ,6.4
times higher by 24 hrs p.i. Overall, during early infection (2–
12 hrs p.i.), there was no significant difference in levels of viral
genome in the nucleus of infected cells cultured under hypoxia vs.
normoxia, suggesting that the B19V genome that has entered the
cells was transported to the nucleus at a similar rate under the two
conditions, and that the difference in viral genome number at later
stages of infection was likely due to increased viral DNA
replication in cells cultured under hypoxia.
We also tested the absolute effects of hypoxia on B19V DNA
replication, in cells transfected with a B19V infectious DNA (M20)
[26]. Since CD36
+ EPCs are known to be difficult to transfect,
with the only somewhat successful method (nucleofection) causing
Figure 1. Support of B19V infection of CD36
+ EPCs under hypoxia vs. normoxia. (A) Status of CD36
+ EPCs cultured under hypoxia vs.
normoxia. Day 4 HSCs were ex vivo expanded under either hypoxia or normoxia to produce CD36
+ EPCs. At day 8, the cells were profiled by flow
cytometry analysis for surface antigens indicated. Numbers shown in each plot are percentage of positive cells. (B&C) B19V infection under hypoxia
vs. normoxia. Day 8 CD36
+ EPCs were infected with B19V at an MOI of 5,000 gc/cell. (B) At 48 hrs p.i., immunofluorescence staining was performed
using anti-NS1 or anti-11 kDa antiserum. DAPI was used to stain the nucleus. Confocal images were taken at a magnification of 406(objective lens)
using an Eclipse C1 Plus confocal microscope controlled by EZ-C1 software (Nikon). (C) At 48 hrs p.i., mRNA was extracted from infected cells, and the
levels of B19V VP2-encoding mRNA per b-actin mRNA were quantified.
doi:10.1371/journal.ppat.1002088.g001
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semipermissive UT7/Epo-S1 cells. The M20 infectious DNA has
been shown to replicate in UT7/Epo-S1 cells, though very poorly
[26,28]. Surprisingly, the M20 DNA replicated efficiently in cells
cultured under hypoxia, at a rate of ,78 times higher than in cells
cultured under normoxia (Figure 4A, compare lanes 6 and 8), and
the ssDNA viral genome was clearly detected in transfected cells
cultured under hypoxia (Figure 4A, compare lanes 5 and 7). More
importantly, infectious virions were produced efficiently at a level
of ,150 ffu per ml from M20-transfected UT7/Epo-S1 cells
cultured under hypoxia, but not from the counterparts cultured
under normoxia (Figure 4B–D).
Taken together, these results show that growth in the context of
hypoxia facilitates B19V infection at the stage of viral DNA
replication within the nucleus, rather than promoting viral entry,
intracellular trafficking through the cytoplasm, or packaging of the
ssDNA viral genome. Moreover, our results provide a practical
approach to generate sufficient B19V progeny virions from the
infectious clone for genetic studies in the future.
B19V infection of hypoxia-cultured CD36
+ EPCs is not
facilitated by hypoxia-inducible factor a (HIFa)
We next sought to identify the cellular signaling pathways that
contribute to the increased B19V DNA replication observed in
CD36
+ EPCs under hypoxia. HIF1a is a transcription factor that
is the key initiator upregulated in cells under hypoxia [29,30], and
it has been shown to interact with a putative HIF-binding site
Figure 2. Production of progeny virus in CD36
+ EPCs under hypoxia vs. normoxia. Day 8 CD36
+ EPCs were infected with B19V at a low MOI
(1,000 gc/cell) under either hypoxia or normoxia. At 72 hrs p.i., infected cells were lysed by repeated freeze-thaw cycles, to release progeny virus.
After a brief spin, one third of the lysate from each culture was used to infect fresh day 8 CD36
+ EPCs cultured under the same conditions. (A&B)A t
each passage, infected cells were examined by immunofluorescence to detect staining with an anti-B19V capsid antibody (detection for assembled
capsids). (C&D)The production of progeny virus was quantified by qPCR-based assessment of the number of copies of the viral genome (C) and
assessed for infectious units by titration of ffu (D).
doi:10.1371/journal.ppat.1002088.g002
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HIF1a was elevated in hypoxia-cultured CD36
+ EPCs (Figure 5A).
To examine whether hypoxia has an effect on B19V transcription
from the P6 promoter, we generated a lentivirus that bears a GFP
expression cassette driven either by the B19V P6 promoter (Lenti-
P6-GFP) or by a mutant P6 promoter in which the HBS has been
knocked out [Lenti-P6(DHBS)-GFP] [18] (Figure 5B). As shown in
Figure 5C, the mean fluorescence intensity (MFI) values for both
Lenti-P6-GFP- and Lenti-P6(DHBS)-GFP-transduced cells were
decreased in the cells cultured under hypoxia, by ,20%
(Figure 5C, compare panels NRNt oN RH), indicating that the
wild-type and mutant P6-promoters do not differ in their response
to hypoxia or in their response to the stabilized HIF1a. However,
we observed that the MFI values of the Lenti-P6(DHBS)-GFP-
transduced cells were consistently lower than those of the Lenti-
P6-GFP-transduced cells under both culture conditions
(Figure 5C). These findings imply that transcription factors other
than HIF1a may bind to the region spanning the 59ACGT39
sequence of the P6 promoter. We also transfected a CMV
promoter-driven P6-GFP into UT7/Epo-S1 cells and examined
the GFP expression in response to HIF1a that was stabilized by
CoCl2 [31] (Figure S1C–F). The stabilized HIF1a expression
failed to alter GFP expression in transfected cells, consistent with
the observation that B19V P6 promoter activity does not respond
to the level of HIF1a expression in CD36
+ EPCs cultured under
hypoxia.
Figure 3. B19V DNA replication, virus entry and intracellular trafficking in CD36
+ EPCs under hypoxia vs. normoxia. B19V DNA
replication, entry and trafficking were assessed in day 8 CD36
+ EPCs infected with B19V at an MOI of 5,000 gc/cell under each condition. (A&B) At the
indicated times p.i., Hirt DNA was extracted and analyzed by Southern blotting. (A) The full blot is shown. M, marker, a 5.6-kb B19V DNA; N, normoxia;
H, hypoxia; RF, replicative form DNA; dRF: double replicative form DNA; ssDNA: single-stranded DNA. (B) The bands of the viral RF DNA and ssDNA
genome in the blot were quantified and values shown are relative to the normoxia-cultured sample of either collected at 24 hrs p.i. (upper panel) or
at 2 hrs p.i. (lower panel). (C) B19V entry into the cell and virus replication were assessed. The entered number of viral genomes within the cell under
each condition was assessed, and is shown in green bars. Duplicated sets of treated cells were maintained under the respective condition until 48 hrs
p.i., at which point total viral DNA was quantified. Results are shown as absolute number of genomic copies per cell in red bars. (D) The rate of B19V
trafficking to the nucleus and replication was measured in infected cells, at the indicated time points. The numbers of genome copies per cell in the
nucleus are shown.
doi:10.1371/journal.ppat.1002088.g003
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replication in cells under hypoxia, using a pharmacological
inhibitor of diacylglycerol kinase (R59949), which decreases the
level of HIF1/2a by activating HIF prolylhydroxylases (PHD) [32]
and proteasome-dependent degradation of hydroxylated HIFa
[19]. Application of 2 mM R59949 resulted in ,30% inhibition of
HIF1a expression, but the B19V VP2-encoding mRNA remained
at the same level as in the control (Figure 5D). At 10 mM R59949,
HIF1a was inhibited by more than 60%, and the viral VP2-
encoding mRNA level decreased slightly (Figure 5D), possibly as a
result of the known gentle cytotoxicity of the inhibitor (Figure
S4A). This result supports the notion that HIF1/2a does not
facilitate B19V infection in CD36
+ EPCs cultured under hypoxia.
We also employed lentiviruses expressing HIF1a-specific small
hairpin RNAs (shRNAs) to test the effects of HIF1a knockdown on
B19V infection. Although HIF1a shRNA-expressing lentiviruses
decreased HIF1a expression by ,70% compared to the scrambled
shRNA-expressing control lentivirus, they failed to alter the
number of cells expressing NS1 at detectable levels (Figure 5E). In
addition, the expression of HIF2a- and HIF3a-specifc shRNAs
had no significant effects on B19V infection of CD36
+ EPCs under
hypoxia (Figure S2). We also applied shRNAs targeting three
isoforms of HIF PHD to promote HIFa expression in CD36
+
EPCs cells cultured under normoxia. Although moderate increases
in HIF1a expression were achieved in HIF PHD1-3 shRNA-
transduced cells under normoxia, none of the three shRNAs
Figure 4. B19V DNA replication and de novo production of infectious virions in UT7/Epo-S1 cells under hypoxia. (A) The rate of
replication of transfected B19V infectious DNA (M20) was measured in UT7/Epo-S1 cells under hypoxia (H) vs. normoxia (N). UT7/Epo-S1 cells were
pre-cultured under hypoxia for 2 days prior to nucleofection with the M20 DNA. At the times indicated, Hirt DNA was prepared, digested with (+)o r
without (2) Dpn I, and analyzed by Southern blotting. dRF, RF and ssDNA bands are indicated. (B, C&D) B19V infectious virions produced from
nucleofection of the M20 DNA into UT7/Epo-S1 cells was boosted under hypoxia. UT7/Epo-S1 cells cultured under hypoxia (H) or normoxia (N) were
nucleofected with the M20 DNA. At 48 hrs post-nucleofection, the cells were pelleted and resuspended in CD36
+ EPC expansion medium followed by
three cycles of freeze-thaw and a briefly spin. This virus preparation was used to infect hypoxia-cultured CD36
+ EPCs. At 48 hrs p.i.,
immunofluorescence staining was performed using anti-NS1 (B), images were acquired at a magnification of 206(objective lens) using an Eclipse Ti-S
inverted microscope (Nikon) controlled by MetaMorph software (Molecular Devices); and the levels of VP2-encoding mRNA per b-actin mRNA were
quantified (C). Yields of infectious virions in ffu were calculated (D). ND, not detectable.
doi:10.1371/journal.ppat.1002088.g004
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(GFP
+) cells (Figure 5F).
Collectively, these results demonstrate that HIFa stabilized (by
either hypoxia or PHD inhibition) does not contribute to the
increased efficiency of B19V infection of CD36
+ EPCs cultured
under hypoxia.
Hypoxia reduces the differentiation potential and the
proliferation rate of CD36
+ EPCs
As Epo/EpoR signaling is critical to B19V replication [24], we
hypothesized that CD36
+ EPCs may undergo changes in Epo/
EpoR signaling under hypoxia. To test this hypothesis, we
examined the levels of EpoR on cell surface and the phosphor-
ylation status of both EpoR and Jak2 in CD36
+ EPCs under both
conditions. We found that at day 9 EpoR was increased ,2-fold
on the cell surface of CD36
+ EPCs under hypoxia (Figure 6A), but
that the level of phosphorylated EpoR (pEpoR) was decreased by
,40% in cells under hypoxia (Figure 6A&B). Nevertheless, Jak2
phosphorylation (pJak2) was similar in cells cultured under the two
conditions (Figure 6A&B). These findings led us to further
examine the signaling pathways downstream of Epo/EpoR
signaling. As shown in Figure 6C, the total levels of cellular EpoR
were elevated in cells cultured under hypoxia, consistent with the
increase in cell surface expression of EpoR (Figure 6A). Strikingly,
phosphorylated STAT5A (pSTAT5A), the major outcome of
Epo/EpoR signaling and a key driver of erythropoiesis [25], was
elevated significantly in cells cultured under hypoxia, whereas
phosphorylated ERK (pERK), which is critical for the prolifera-
tion and survival of erythroid progenitors [33,34], was clearly
decreased in cells cultured under hypoxia (Figure 6C). In line with
these observations, CD36
+ EPCs proliferated more slowly under
hypoxia than under normoxia, as evidenced by both cell counts
and an ATP-based cell proliferation assay (Text S1 and Figure
S3A&B). Consistent with this finding, the percentage of S-phase
cells among normoxia-cultured CD36
+ EPCs was higher on
average than that among their hypoxia-cultured counterparts, and
the level of the sub-G0 population of CD36
+ EPCs under hypoxia
lagged behind that of CD36
+ EPCs under normoxia (Figure S3C).
Figure 5. Regulation of B19V infection of CD36
+ EPCs by HIFa under hypoxia vs. normoxia. (A) HIF1a levels in CD36
+ EPCs cultured under
normoxia (N) or hypoxia (H). Cell lysates were prepared on the indicated days and were analyzed by Western blotting with anti-HIF1a and anti-b-
actin. (B&C) Effects of the putative HIF-HBS in the P6 promoter. Day 7 hypoxia- or normoxia-cultured CD36
+ EPCs were transduced with Lenti-P6-GFP
or Lenti-P6(DHBS)-GFP (B), and then were either maintained under normoxia (RN) or hypoxia (RH). At 48 hrs post-transduction, level of GFP
expression (as MFI) was measured by flow cytometry. (D) Effects of R59949 on B19V infection. Day 8 hypoxia-cultured CD36
+ EPCs were treated with
R59949 at the final concentrations shown. At 24 hrs post-treatment, cells were collected for HIF1a detection by Western blotting, or infected with
B19V at an MOI of 1,000 gc/cell. At 48 and 72 hrs p.i., the levels of VP2-encoding mRNA per b-actin mRNA were quantified. (E&F) Effects of HIF1a and
PHD knockdown on B19V infection. Day 7 CD36
+ EPCs cultured under each condition were transduced with the indicated lentiviruses. At 48 hrs post-
transduction, cells were infected with B19V (at MOIs of 2,000 and 4,000 gc/cell for hypoxia- and normoxia-cultured cells, respectively). At 48 hrs p.i.,
the expression levels of NS1 (as % of positive cells) and HIF1a (as MFI) were analyzed by flow cytometry in lentivirus-transduced (GFP
+) cells. Dashed
reference lines were selected arbitrarily to show the relative position of the peaks, and Bkg (background) represents the secondary antibody only
control.
doi:10.1371/journal.ppat.1002088.g005
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+ EPCs
under hypoxia. Phosphorylated AKT (pAKT) remained at a
similar level in cells cultured under the two conditions (Figure 6D),
suggesting that AKT may not play an important role in the
enhancement of B19V infection of CD36
+ EPCs in the context of
hypoxia.
We further probed the differentiation status of these cells with
respect to intracellular makers of erythroid differentiation [35].
These include GATA1, GATA2 and hemoglobin-c. We found
that the levels of GATA1, GATA2 and hemoglobin-c, as well as
phosphorylation of the GATA1 were higher in normoxia-cultured
CD36
+ EPCs than in their hypoxia-cultured counterparts
(Figure 6E), indicating that the normoxia-cultured CD36
+ EPCs
are likely more differentiated.
B19V infection is facilitated by phosphorylated STAT5A
Since STAT5A was upregulated in CD36
+ EPCs under hypoxia
(Figure 6C) and inhibition of Jak2 phosphorylation is known to
block B19V replication [24], we hypothesized that STAT5A
signaling is critical to supporting B19V replication in CD36
+ EPCs
cultured under normoxia, and may be responsible for the increase
in efficiency of B19V infection in the cells cultured under hypoxia.
We tested this using three pharmacological inhibitors (the Jak2
inhibitor AG490, a STAT5B inhibitor and a STAT3 inhibitor),
examining their influence on B19V infection under normoxia
(Figure 7A&B). A 70% inhibition of STAT5A phosphorylation by
5 mM AG490 resulted in failure to detect the VP2-encoding
mRNA (Figure 7B) in the absence of significant cytotoxicity
(Figure S4A), as we had previously demonstrated [24]. At the
maximum concentration of 200 mM, the STAT5B inhibitor
reduced production of the VP2-encoding mRNA to ,40% of
that seen in the DMSO control. The STAT3 inhibitor had no
significant effect on the level of the VP2-encoding mRNA
(Figure 7B). The lesser sensitivity of B19V infection to the
STAT5B inhibitor is likely due to cross-inhibition of the STAT5
SH2 domain [36] as Epo/EpoR signaling does not activate
STAT5B [37]. We therefore focused on the role of STAT5A
activation in B19V infection.
To confirm that STAT5A plays a critical supportive role in
B19V infection of CD36
+ EPCs, we generated two lentiviruses that
express a constitutively active STAT5A, STAT5A(1*6) [38].
Expression of the constitutively active STAT5A(1*6), with the 59
untranslated region (UTR) either present [UTRSTAT5A(1*6)] or
absent [STAT5A(1*6)], in normoxia-cultured CD36
+ EPCs led to
an ,2.5-fold increase in STAT5A phosphorylation in transduced
(GFP
+) cells over that seen in the GFP expression control
(Figure 7C). As a result, the NS1-expressing cell population
among the GFP
+ cells transduced with either of the STAT5A(1*6)-
expressing lentiviruses increased 2-fold compared to that in Lenti-
GFP control-transduced (GFP
+) cells (Figure 7C). These results
strongly suggest that upregulation of STAT5A phosphorylation
facilitates B19V infection of CD36
+ EPCs cultured under
normoxia.
From the point that STAT5A phosphorylation was increased in
CD36
+ EPCs cultured under hypoxia (Figure 6C), we generated
two lentiviruses that express validated shRNAs to specifically
knock down STAT5A expression in these cells. Cells treated with
the shRNA-expressing lentiviruses did not show drastic change of
the cell cycle and cell death (sub G0 phase) (Figure S4B), indicating
that application of lentiviral vectors is safe to CD36
+ EPCs. As
shown in Figure 7D, the levels of both STAT5A expression and
STAT5A phosphorylation were significantly reduced (by ,50%
and 40%, respectively), in the cells expressing the SATA5A
shRNA1 and shRNA2, compared to levels in control cells
expressing the scrambled shRNA (Figure 7D, panels STAT5&p-
STAT5). Correspondingly, NS1 expression was significantly
decreased in the cells in which STAT5A phosphorylation was
reduced (Figure 7D, panel NS1).
All three lines of evidence presented here confirm that STAT5A
phosphorylation is critical to B19V infection of CD36
+ EPCs in
the context of normoxia, and that elevated phosphorylation of
STAT5A in CD36
+ EPCs under hypoxia, at least partially,
Figure 6. Characterization of CD36
+ EPCs cultured under normoxia vs. hypoxia. Day 4 HSCs were expanded under either hypoxia (H) or
normoxia (N). (A) At day 9, cell surface EpoR, intracellular pEpoR and pJak2 were analyzed by flow cytometry. Numbers shown are MFI. (B, C&D)O n
the days indicated, the cells were analyzed for the expression of proteins by Western blotting. (E) At the days indicated, Western blotting was used to
assess the levels of intracellular markers of erythroid differentiation, including GATA1 (total and phosphorylated), GATA2 and hemoglobin-c.
doi:10.1371/journal.ppat.1002088.g006
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under hypoxia.
B19V infection is negatively regulated by MEK/ERK
signaling
The downregulation of ERK phosphorylation in CD36
+ EPCs
cultured under hypoxia (Figure 6C) led us to speculate that
inhibition of ERK phosphorylation affects B19V infection of
CD36
+ EPCs. We thus examined the role of this pathway during
B19V infection of CD36
+ EPCs cultured under normoxia,
selecting three pharmacological inhibitors of the MEK/ERK
pathway: FR180204 (ERK-specific) [39], PD98059 and U0126
(MEK-specific) [40]. Application of each of these inhibitors
enhanced the effectiveness of B19V infection in treated CD36
+
EPCs, as detected by significant increases in levels of B19V VP2-
encoding mRNA (Figure 8A). Most strikingly, application of
10 mM U0126, an MEK-specific inhibitor, resulted in 5-fold
increase in the level of VP2-encoding mRNA. Similarly, U0126
treatment of B19V-infected UT7/Epo-S1 cells resulted in a 10-
fold increase of the VP2-encoding mRNA (Figure 8B). These
results suggest that inhibition of the MEK/ERK pathway
promotes B19V infection in both CD36
+ EPCs and UT7/Epo-
S1 cells cultured under normoxia.
To confirm such a role for the MEK/ERK pathway during
B19V infection, we generated lentiviruses expressing shRNAs
validated to specifically knock down the upstream regulators
MEK1 and MEK2. Inhibition of either MEK1 or MEK2 by
applying MEK1 or MEK2 shRNAs led to an ,2-fold increase in
the level of the VP2-encoding mRNA (Figure 8C), a decrease in
the phosphorylation of their substrate (pERK1/2), and an ,3-fold
increase in the NS1-expressing cell population (Figure 8D).
Moreover, we transduced a retrovirus expressing a constitutively
active MEK (MEKDD) [41] into CD36
+ EPCs cultured under
hypoxia, and tested it for a role in increasing MEK phosphory-
lation and interfering with B19V infection. Not surprisingly,
overexpression of MEKDD resulted in elevated pERK1/2 levels
(Figure 8F), a reduction in the levels of the VP2-encoding mRNA
(by ,5-fold; Figure 8E) and a reduction in the NS1-expressing cell
Figure 7. Regulation of B19V infection of CD36
+ EPCs by phosphorylated STAT5A. (A&B) Effect of inhibiting STAT phosphorylation on
B19V infection. Day 8 CD36
+ EPCs cultured under normoxia were pre-treated with pharmacological inhibitors of phosphorylation at the indicated
final concentration, or with 0.5% DMSO (control). At 24 hrs post-treatment, the cells were analyzed by Western blotting for the inhibitory effects on
phosphorylation (A); or were infected with B19V (at an MOI of 5,000 gc/cell) (B). At 48 hrs, p.i., the infected cells were assessed for the level of B19V
VP2-encoding mRNA per b-actin mRNA. (C&D) B19V infection in the context of constitutively active STAT5A and STAT5A-specific shRNAs. Day 7
CD36
+ EPCs cultured either under normoxia (C) or hypoxia (D) were transduced with the indicated lentivirus. At 48 hrs post-transduction, the cells
were infected with B19V at an MOI of 5,000 gc/cell, and at 48 hrs p.i., they were analyzed by flow cytometry for the expression of B19V NS1, STAT5A
and pSTAT5A. The GFP-positive population of lentivirus-transduced cells was selectively gated. Percentages shown in the left column indicate the
level of NS1-expressing cells, and the numbers in the right column the MFI of STAT5A or pSTAT5A. Results shown are representative of at least two
independent experiments. Dashed reference lines in panels C&D were selected arbitrarily to show the relative positions of the peaks, and Bkg
(background) represents the secondary antibody only control.
doi:10.1371/journal.ppat.1002088.g007
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levels in their GFP-expressing controls (Figure 8E&F, Retro-GFP).
Together, all the results we obtained here confirm that the MEK/
ERK pathway negatively regulates B19V infection of CD36
+
EPCs cultured under both normoxia and hypoxia.
B19V infection is not influenced by PI3K/AKT signaling
To exclude a role for the PI3K/AKT pathway in B19V
infection, we firstly used the PI3K-specific pharmacological
inhibitor Wortmannin, to inhibit AKT phosphorylation in
CD36
+ EPCs under normoxia (Figure 9A). The application of
Wortmannin at final concentrations of 0.2, 1, and 2.5 mM failed to
yield a statistical difference in B19V infection, based on
quantification of the VP2-encoding mRNA (Figure 9B). In
addition, we employed lentiviruses that expressed shRNAs
specifically targeting the p110a subunit of PI3K. Although both
shRNA lentiviruses knocked down the level of p110a by ,50%,
neither affected NS1 expression in p110a shRNA-expressing
(GFP
+) cells compared with that in the cells expressing the
scrambled shRNA-expressing (GFP
+) (Figure 9C). Together with
the observation that AKT was not elevated in CD36
+ EPCs under
hypoxia, these results lead us to conclude that the PI3K/AKT
pathway is not directly involved in B19V infection of CD36
+
EPCs.
B19V infection is synergistically facilitated by expression
of a constitutively active STAT5A and application of an
MEK inhibitor
Since we observed that regulation of both STAT5A and MEK/
ERK pathways did not affect each other in facilitating B19V
infection (Figure S5A&B), we next examined whether it is possible
to further modulate B19V infection of normoxia-cultured CD36
+
EPCs by manipulating the STAT5A and MEK/ERK pathways
simultaneously. To this end, we used the constitutively active
STAT5A and the U016 MEK inhibitor in combination to assess
B19V infection. As shown in Figure 9A, individually U0126
treatment and STAT5A(1*6)-expression led to an increase in the
NS1-expressing cell population, from ,12% in the control groups
Figure 8. Regulation of B19V infection of CD36
+ EPCs by MEK/ERK pathway. (A&B) Day 8 CD36
+ EPCs (A) or UT7/Epo-S1 cells (B) cultured
under normoxia were pre-treated with the indicated pharmacological inhibitors of MEK/ERK at 24 hrs prior to B19V infection (at an MOI of 5,000 gc/
cell). At 48 hrs, p.i., the infected cells were quantified for the level of B19V VP2-encoding mRNA per b-actin mRNA. (C&D) Day 7 CD36
+ EPCs cultured
under normoxia were transduced with lentiviruses expressing MEK-specific shRNAs or the scrambled shRNA (control). (E&F) Day 7 CD36
+ EPCs
cultured under hypoxia were transduced with retroviruses expressing constitutively active MEK (Retro-MEKDD) and GFP (Retro-GFP; control). The
transduced normoxia- or hypoxia-cultured CD36
+ EPCs were infected with B19V at MOIs of 5,000 gc/cell at 48 hrs post-transduction. Groups of
treated cells were quantified for the level of B19V VP2-encoding mRNA per b-actin mRNA (C&E), and analyzed for expression of B19V NS1 and
phosphorylated ERK1/2 (pERK1/2) by flow cytometry. The percentages shown in the left column indicate the level of NS1-expressing cells, whereas
the numbers shown in the right column represent the MFI of pERK1/2 expression (D&F). Results shown are representative of at least two independent
experiments. Dashed reference lines in panels D&F were selected arbitrarily to show the relative position of the peaks, and Bkg (background)
represents the secondary antibody only control.
doi:10.1371/journal.ppat.1002088.g008
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tively, in transduced GFP
+ cells. However, when the treatments
were combined the NS1-expressing population was boosted to a
level of 35%, a level comparable to that seen when CD36
+ EPCs
were infected under hypoxia (38%). This synergistic enhancement
of B19V infection was confirmed by respective increases in the
levels of the VP2-encoding mRNA, progeny virus (packaged viral
genome) and total viral DNA (Figure 10B, C&D, respectively).
Notably, we did not select the transduced GFP
+ cell population
[STAT5A(1*6)-expressing cells] when quantifying the levels of the
B19V mRNA and DNAs, which may account for the small
difference between these results and those for the hypoxia group
with respect to the NS1-expressing cell percentage, which was
determined in cells selected for GFP expression. The lentivirus
transduction efficiency (GFP
+ rate) was ,50%.
These results demonstrated that we have recapitulated the
increased B19V infection of CD36
+ EPCs under hypoxia by
manipulating phosphorylation of both STAT5A and ERK in
CD36
+ EPCs under normoxia.
Discussion
B19V infection shows a remarkable tropism for human
erythroid progenitors in the bone marrow of infected individuals
[42,43]. The microenvironment of bone marrow in both animals
and humans has been suggested to be hypoxic relative to other
tissues, and both HSCs and EPCs are thought to reside in the most
hypoxic microenvironment within the bone marrow [44–46]. In
the current study, we have mimicked the natural ‘‘niches’’ of EPCs
in the bone marrow, demonstrating that B19V infection of ex vivo
expanded EPCs cultured under hypoxia is conducive to sustained
production of progeny B19V in vitro. Our results show that even in
the absence of changes in virus entry or intracellular trafficking,
the hypoxic environment leads to fine tuning of nuclear
microenvironment of B19V-infected EPCs, by regulating phos-
phorylation of STAT5A and MEK, and thereby boosting the
production of B19V progeny virus over 10-fold.
Hypoxia enhances replication of the B19V genome in the
nucleus
The enhancement of B19V infection in EPCs cultured under
hypoxia is due to the increased replication of the viral genome
after it enters the nucleus of cells in the context of hypoxia
(Figure 3A–D). More direct evidence that transfected B19V
infectious DNA replicated ,80 times more rapidly in UT7/Epo-
S1 cells under hypoxia than under normoxia further supports the
notion that hypoxia facilitates replication of the viral genome in
the nucleus. Our study is the first to show that the ssDNA B19V
genome and an a high level, up to ,150 ffu/ml, of progeny virus
are produced following transfection of the B19V infectious DNA
into UT7/Epo-S1 cells [26]. However, the ratio of ssDNA/RF
DNA (1:4) remained lower than that observed during B19V
infection of EPCs (,1:1). This is likely due to the semi-
permissiveness of UT7/Epo-S1 cells to B19V infection; even
following infection, progeny virus is produced inefficiently [13,47].
Given that parvovirus DNA replication occurs by a ‘‘rolling
hairpin’’ model [4], i.e., synthesis of the ssDNA genome and its
packaging into the assembled virion take place simultaneously
[48]. We believe that replication of the B19V RF DNA, but not
generation of the ssDNA B19V genome or capsid assembly, is the
key event of the B19V life cycle that is elevated in B19V-infected
Figure 9. Regulation of B19V infection of CD36
+ EPCs by the PI3K/AKT pathway. (A&B) Day 8 CD36
+ EPCs cultured under hypoxia were
treated with the PI3K-specifc inhibitor Wortmannin at the final concentrations indicated. At 24 hrs post-treatment, the cells were infected with B19V
at an MOI of 5,000 gc/cell, and at 48 hrs p.i., were tested for AKT phosphorylation (pAKT) by Western-blotting (A). Also, the levels of VP2-encoding
mRNA per b-actin mRNA were quantified (B). (C) Day 7 CD36
+ EPCs cultured under normoxia were transduced with lentiviruses expressing p110a-
specific shRNAs and scrambled shRNA (control), respectively. At 48 hrs post-transduction, all groups of transduced cells were infected with B19V at an
MOI of 5,000 gc/cell. At 48 hrs p.i., levels of B19V NS1 and of the PI3K subunit p110a were analyzed by flow cytometry. The GFP-positive population
of lentivirus-transduced cells was selectively gated. The percentages shown in the left and right columns indicate the level of NS1-expressing cells
and the MFI of p110a expression, respectively. Results shown are representative of at least two independent experiments. Dashed reference lines
were selected arbitrarily to show the relative position of the peaks, and Bkg (background) represents the secondary antibody only control.
doi:10.1371/journal.ppat.1002088.g009
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for performing reverse genetics of B19V, which has not been
possible before this study [26,49].
In the context of hypoxia, the canonical PHD/VHL/HIFa
pathway does not contribute to the regulation of B19V
infection
In the context of normoxia, HIFa is hydroxylated by PHDs and
thus targeted by an E3 ubiquitin ligase in the VHL (von Hippel-
Lindau protein) complex, followed through a proteasome-
mediated degradation pathway [19]. In the context of hypoxia,
by contrast, the activities of PHD1-3 are downregulated and the
increased HIFa activity both promotes the expression of genes
whose products sense hypoxia and activates signal transduction
pathways that lead to physiologically appropriate changes [29,30].
In our studies, under hypoxia, HIFa knockdown failed to affect
B19V infection (Figure 5E&S2); and in the context of normoxia,
although PHD1-3 knockdown resulted in a significant increase in
the level of HIF1a even in the context of normoxia, it failed to
affect B19V infection (Figure 5F). Moreover, regardless of whether
HIF1a expression in EPCs was increased under normoxia (using
shRNAs to specially knock down PHD1-3) or decreased under
hypoxia (using shRNAs to specially knock down HIF1a), the
phosphorylation of both STAT5A and ERK was not affected
(Figure S6). Therefore, our results indicate that hypoxia-enhanced
B19V infection of EPCs is independent of both HIFa and PHD.
Strikingly, only a few cases of hypoxia-responding stress that are
independent of the canonical PHD/VHL/HIFa pathway have
been reported [19,50]. Therefore, our studies on the hypoxia-
enhanced B19V infection of EPCs demonstrate the involvement of
two novel mechanisms (i.e., hypoxia-induced STAT5A and
hypoxia-suppressed MEK signaling) in the regulation of hypox-
ia-responding EPC stress, independent of HIFa/PHD, and
suggesting that these create a ‘‘niche’’ for B19V DNA replication
in the nucleus.
Hypoxia-cultured EPCs possess less differentiation
potential than their normoxia-cultured counterparts
EPCs expanded under either condition are at similar stages of
differentiation phenotypically (Figure 1A). Notably, however,
probing of the intracellular markers of erythroid differentiation
(GATA1, GATA2 and hemoglobin-c) revealed that hypoxia-
cultured EPCs are slightly less differentiated than their normoxia-
cultured counterparts (Figure 6C). This is consistent with a recent
report that expression of erythroid transcription factors, e.g.,
GATA1 and EKLF, was delayed and decreased in EPCs cultured
Figure 10. Regulation of B19V infection of CD36
+ EPCs by combinatorial STAT5A upregulation and MEK inhibition. CD36
+ EPCs
cultured under normoxia were transduced with Lenti-STAT5A(1*6) at day 7, pre-treated with U0126 at a final concentration of 10 mM at day 8, or were
subjected to both treatments. At day 9, the cells were infected with B19V (at an MOI of 4,000 gc/cell). Day 9 CD36
+ EPCs cultured under hypoxia and
infected with B19V served as a control. (A) At 48 hrs p.i., the GFP-positive population of lentivirus-transduced cells was selectively gated, and
analyzed for NS1 expression by flow cytometry; the percentage of positive cells is indicated on right side of each panels. The GFP-positive population
of lentivirus-transduced cells was selectively gated. (B, C&D) At 48 hrs p.i., the infected cells without selection of the GFP-positive population were
quantified for the level of B19V VP2-encoding mRNA per b-actin mRNA. The numbers of virus particles (packaged viral DNA) produced (C), and the
total viral DNA in the Hirt DNA samples extracted from the infected cells (D) were quantified by qPCR. The numbers shown in panels C&D are levels of
these copy numbers relative to those in the control group (arbitrarily set to 1). A representative result of three independent experiments is shown in
each of the panels.
doi:10.1371/journal.ppat.1002088.g010
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erythroid lineage-specific transcription factors that specifically
bind to and activate genes important for the proper differentiation
of erythroid cells [52]. In this context, the decrease in GATA1
usually results in a low expression level of EpoR. However, in the
case of EPCs cultured under hypoxia, more EpoR was expressed
at the cell surface in spite of the fact that the levels of
phosphorylated EpoR were low (Figure 6A). This finding supports
the notion that negative feedback inhibits over-activation of EpoR
[53]. Upon Epo ligation, EpoR is immediately phosphorylated,
and this leads to a rapid receptor internalization and degradation,
by both proteasomal and lysosomal mechanisms [54]. We
speculate that in EPCs under hypoxia, either EpoR phosphory-
lation is less sensitive to Epo ligation, or the rate of ligation is
slower than that in the cells under normoxia. This may leads to
slower EpoR internalization and degradation, manifesting pheno-
typically as longer retention on the cell surface, and reduced
phosphorylated EpoR intracellularly. The reduced level of
phosphorylated EpoR leads to downregulation of GATA1 and
GATA2 in EPCs cultured under hypoxia. Thus, we suggest that
EPCs are less differentiated in the context of hypoxia, and that the
apparent increase in EpoR in these cells is likely the result of
decreased degradation.
STAT5A positively regulates B19V infection
In cells of the erythroid lineage, STAT5A is generally
considered to be phosphorylated by Jak2 [25]. Several important
STAT5A target genes, such as Oncostatin M, Pim, SOCS, Bcl-xL
and D-type cyclins, are required for erythropoiesis [25]. However,
Jak2-independent STAT5A phosphorylation has also been
reported in cells of erythroid lineage [55]. This is further
supported by our results that although hypoxia did not lead to
changes in levels of phosphorylated Jak2, STAT5A phosphoryla-
tion was increased over 2-fold (Figure 6C). We thus hypothesize
that in EPCs STAT5A may be a substrate for other kinases in
addition to Jak2, at least in the context of hypoxia. STAT5A-
driven erythroid differentiation is largely dependent on the
erythroid-specific transcription factor GATA1, and STAT5A-
driven proliferation appears to be independent of GATA1 [56].
However, over-activation of STAT5A does not induce GATA1
expression significantly [57]. In fact, we observed that GATA1
levels were decreased in EPCs cultured under hypoxia whereas
STAT5A was upregulated, suggesting that STAT5A-actviated
B19V DNA replication is likely GATA1-independent. We
hypothesize that these GATA1-independent STAT5-targeted
genes [56], e.g., Oncostatin M, Pim and SOCS, likely play critical
roles in regulating B19V DNA replication.
The MEK/ERK pathway negatively regulates B19V
infection
The MEK/ERK pathway is critical to Epo stimulation-
dependent erythroid cell proliferation and survival, which is
mediated by the Grb2-Ras-Raf1 pathway [25]. The levels of ERK
expression and activation fine-tune the balance between prolifer-
ation and differentiation of erythroid progenitors [58]. In EPCs
under hypoxia, the decrease in EpoR phosphorylation may result
in a reduction of ERK phosphorylation (Figure 6C), and this
explains the reduced EPC proliferation in the context of hypoxia
(Figure S3A&B). Despite the slight change in differentiation status
and slow proliferation rate of EPCs under hypoxia, these cells still
expressed similar levels of the major erythroid phenotypic markers
and B19V receptors, suggesting that the balance between the two
processes keeps them moving through erythropoiesis.
The MEK/ERK pathway has been shown to be upregulated
during infection by various viruses, and in the context of certain
RNA and DNA viruses has been implicated as a positive regulator
of both virus entry and intracellular trafficking during infection
[59], for some DNA viruses as a positive regulator of virus
replication through regulating the cell cycle [60]. Notably,
inhibition of MEK or its substrate ERK significantly decreases
virus infection. Our findings clearly show that the MEK/ERK
pathway is a negative regulator of B19V infection in EPCs, a role
unique among those for this pathway in viral infection. Notably,
the B19V small non-structural 11 kDa protein has been shown in
vitro to interact with Grb2 specifically [61], a crucial adaptor for
the activation of Ras/Raf1 and, in turn, for MEK/ERK signaling,
which is activated by phosphorylation of EpoR tyrosine residue
489 [25]. These lines of evidence lead us to postulate that, during
B19V infection, 11 kDa interacts with Grb2 to inhibit MEK/
ERK signaling, thereby facilitating B19V DNA replication.
In erythroid cells, the ERK1/2 pathway is involved in the early
proliferative phases of erythropoiesis [34], and in the inhibition of
terminal erythroid differentiation [33]. Our discovery that S-phase
was delayed in hypoxia-cultured EPCs (Figure S4B), and that
hypoxia inhibited cell proliferation ,2-fold, can be explained by
decreased level of ERK under hypoxia. Notably, B19V infection
of EPCs showed a remarkable inhibition of cell proliferation, and
cell cycle arrest [62]. Although this B19V-induced anti-prolifer-
ation effect and cell cycle arrest have been shown to be beneficial
to B19V replication, the underlying mechanism remains unknown
[62]. ERK1/2 translocate to the nucleus, and directly or indirectly
phosphorylate many transcription factors [63]. We hypothesize
that the reduced ERK1/2 activation in EPCs produces an optimal
microenvironment for B19V DNA replication in the nucleus.
Given that downregulation of the MEK/ERK pathway does not
increase phosphorylation of STAT5A (Figure S5), the two
pathways appear to function independently.
In conclusion, the balanced homeostasis of EPCs under
hypoxia, accompanied by the upregulation of phosphorylated
STAT5A and downregulation of ERK activity, provides B19V
with a nuclear microenvironment optimal for replication of its
genome, independent of HIFa expression. Thus, our study reveals
the factors that are critical to B19V replication and raise infection
of EPCs to a productive level, in a process that likely mimics native
B19V infection of human bone marrow.
Materials and Methods
CD36
+ EPCs and UT7/Epo-S1 cells
Ex vivo expansion of CD36
+ EPCs. CD34
+ hematopoietic
stem cells (HSCs) derived from human bone marrow were
purchased from the National Disease Research Interchange
(NDRI), Philadelphia, PA. Upon arrival in the laboratory
(defined as day 0), these cells were cultured in CD36
+ EPC
expansion medium [16,27] at 5% CO2 and 21% O2 at 37uC
(normoxia) until day 4, and were then frozen in liquid nitrogen at
0.5610
6 cells/vial. These cells were defined as day 4 HSCs
[16,27]. The Day 4 HSCs were thawed and cultured in the same
expansion medium, under either normoxia (5% CO2 and 21%
O2) or hypoxia (5% CO2 and 1% O2)a t3 7 uC until the times of
treatment and B19V infection as indicated in the figure legends.
The hypoxia condition was achieved using the three-door
chamber of the HERAcell 150 tri-gas incubator (Thermo Fisher).
UT7/Epo-S1 cells. UT7/Epo-S1 cells were obtained from
Dr. Kevin Brown, with permission from Dr. Kazuo Sugamura,
and were grown as described previously [11,47].
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Viremic plasma (no.: P32) was obtained from ViraCor-IBT
Laboratories (Lee’s Summit, MO), and the numbers of B19V
genome copies (gc) per milliliter (10
12 gc/ml) was quantified as
previously described [64]. B19V infection was carried out by
adding the B19V-containing plasma or lysates of infected cells
directly to the culture. Multiplicity of infection (MOI) used for
each experiment is indicated in the corresponding figure legend.
Nucleofection
UT7/Epo-S1 cells were electroporated with 2 mg of a B19V
infectious DNA (M20), which was digested from the B19V
infectious clone pM20 [26], or indicated plasmids using the
Amaxa Nucleofector (Lonza) as described previously [27].
Assessment of virus infection
Immunofluorescence assay. Immunofluorescence assay
was performed followed a protocol described previously [47].
First antibodies were as follows: rat anti-B19V NS1, anti-11 kDa
antiserum [27], mouse anti-capsid monoclonal antibody
(Millipore, MAB8293) at 1:100 dilution in PBS-FCS, for 1 hrs at
37uC. Secondary antibodies were fluorescein isothiocyanate
(FITC)-conjugated anti-rat IgG second antibody (Jackson
ImmunoResearch Laboratories) and FITC-conjugated anti-
mouse IgG (F9006, Sigma). DAPI was used to stain the nucleus.
Reverse transcription (RT)–quantitative PCR (qPCR) for
quantification of viral mRNA transcripts, qPCR for
quantification of replicated viral DNA and packaged viral
genomes (virus particles) and virus entry assay. All these
assays were performed as described previously [24].
Quantification of virus infectious units. The infectious
units in B19V-containing cell lysates were titrated as fluorescence
focus-forming units (ffu) per ml following the same protocol
described previously [13].
Southern blot analysis of viral DNAs. Hirt DNA was
extracted from the cells and analyzed using a B19V probe as
described previously [64]. Blots were exposed to a GE phosphor
imaging screen, and quantified using a Phosphor imager (Typhoon
9400) and the Image Quant TL software v2005 (GE Healthcare).
Virus trafficking assay
Either normoxia- or hypoxia-cultured CD36
+ EPCs were
infected with B19V on day 8 of culture at an MOI of 5,000 gc/
cell. Cells were harvested at the indicated time points (hrs p.i.). At
2 hrs p.i., cell-surface bound virions were removed by treatment
with trypsin (0.25% trypsin in 20 mM EDTA) for 5 min at 37uC
with manual agitation. The cells were washed with PBS, and
nuclear fraction was prepared using the Nuclei EZ Prep Nuclei
isolation Kit (NUC-101, Sigma) and following the manufacturer’s
instructions. The fractions were stored at 280uC until analysis.
The numbers of viral genomes in the nuclear fraction were
quantified by qPCR as described above, and were divided by the
number of the cells collected.
Construction, production, and transduction of retroviral
and lentiviral vectors
Lentiviral vectors expressing shRNAs. Plasmids pLKO-
GFP and pLKO-GFP-Scramble-shRNA were described
previously [24]. The validated shRNA sequences shown in
Table S1 were cloned into pLKO-GFP using the AgeI and
EcoRI sites, to generate the pLKO-GFP-XXX-shRNA plasmids.
Lentiviral vectors expressing proteins. Plasmid pLenti-
GFP-Puro (pLenti) was obtained from Addgene Inc. (Cambridge,
MA). The GFP coding region was replaced with IRES-GFP
(Clontech) using the BamHI and BsrGI sites, and multiple
restriction enzyme sites (EcoRI-EcoRV-SpeI) were added
between the BamHI and IRES sequences, to produce pLenti-
MCS-IRES-GFP. The coding sequences of two constitutively
active forms of STAT5A [UTR STAT5A(1*6) (nt 242–2715) and
STAT5A(1*6) (nt 334–2715)] were amplified from pMX-
STAT5A(1*6)-IRES-GFP (H298R/S710F) [65], and were
inserted between the BamHI and SpeI sites of pLenti-MCS-
IRES-GFP, generating pLenti-UTR-STAT5A(1*6)-IRES-GFP
and pLenti-STAT5A(1*6)-IRES-GFP, respectively.
Plasmid pLenti-P6-GFP was constructed by replacing the CMV
promoter sequence of the pLenti vector between the ClaI and
XbaI sites with the B19V sequence spanning nt 187–564
(GenBank accession no.: AY386330). The HBS mutant was
generated by mutating the putative HBS motif from 59ACGT39
(nt 204–207) to 59TTTT39 [18].
Retroviral vector expressing constitutively active MEK
(MEKDD). The constitutively active MEK gene, MEKDD(S2-
18D&S222D) [41], which was amplified from pBabe-Puro-MEK-
DD (Addgene), was inserted into the BamHI-XbaI-digested
pMSCV-MCS-IRES-GFP-WRE vector [24], to produce
pMSCV-MEKDD-IRES-GFP.
Production and concentration of viral vectors. Lentivirus
was produced and concentrated according to instructions from
Addgene (http://www.addgene.org/plko).
The retroviruses Retro-MEKDD and Retro-GFP (control) were
produced by transfecting GP293 cells (Clontech) with pMSCV-
MEKDD-IRES-GFP and pMSCV-MSC-IRES-GFP-WRE [24],
respectively, together with pCMV-VSVG. The retroviral vectors
were concentrated following the manufacturer’s instructions
(Clontech, cat. No.:PT3132-1).
Lentiviral and retroviral transduction. Concentrated
lentiviral or retroviral vector was added to CD36
+ EPCs at day
7 of culture, at an MOI of ,4 ffu/cell.
Pharmacological inhibitors used in this study
Wortmannin (681675), R59949 (266788), AG490 (658401), a
STAT5B inhibitor (573108), a STAT3 Inhibitor (573102),
FR180204 (328007), PD98059 (513000) and U0126 (662005)
were purchased from EMD Chemicals, and dissolved in DMSO to
generate the recommended stock solutions.
Western blot analysis
Western blot analysis was carried out as previously described
[6]. Antibodies used for Western blotting were as follows: anti-
HIF1a (610959) from BD Biosciences; anti-GATA1 (sc-1234),
anti-pGATA1 (sc-101687), anti-GATA2 (sc-9008), and anti-
hemoglobin-c (sc-21756) from Santa Cruz; anti-EpoR (ab56310)
and anti-pSTAT5B (ab52211) from Abcam; anti-pSTAT5A
(A00253), anti-pJak2 (A00360) and pSTAT3 (A00251) from
GenScript; anti-pERK (4377S) and pAKT (4060S) from Cell
Signaling; anti-pEpoR (2585-1) from Epitomics; and anti-b-actin
(A5441) from Sigma. Secondary antibodies were HRP-conjugated
anti-mouse (A4416) or HRP-conjugated anti-rabbit (A0545) from
Sigma. b-actin was used as a loading control.
Flow cytometry analysis
Cell surface staining was performed essentially as described
previously [24]. The following antibodies were used: Anti-CD34
(340862), CD41 (555465), CD36 (555453), CD71 (554889),
CD235a (555569), and CD49e (555615), purchased from BD
Biosciences; anti-KU80 (NA52) from CalBiochem; anti-Globoside
(1960) from Matreya; and anti-EpoR (ab56310) from Abcam.
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essentially as described previously [66]. The following antibodies
were used: HIF1a (610959) and p110a (611398), purchased from
BD Biosciences; anti-pJak2 (A00360), anti-STAT5A (A00280) and
anti-pSTAT5A (A00253) from GenScript; anti-pERK (4377) from
Cell Signaling; and anti-pEpoR (c-20236-R) from Santa Cruz. For
flow cytometry by GFP selection, the secondary antibody used was
Cy5-conjugated to one of the following: anti-mouse (115-176-146),
anti-rat (112-176-143) or anti-rabbit (111-176-144) from Jackson
ImmunoResearch. In all other analyses, the secondary antibody
was: FITC-conjugated anti-mouse IgG (715-095-151) from
Jackson ImmunoResearch; anti-mouse IgM (F9529); or anti-rabbit
IgG (F9887) from Sigma.
Supporting Information
Figure S1 In UT7/Epo-S1 cells, hypoxia also signifi-
cantly increases B19V infection, and HIF1a does not
activate the B19V P6 promoter. (A&B) UT7/Epo-S1 cells
were infected with B19V at an MOI of 20,000 gc/cell under
either normoxia (N) or hypoxia (H). At 48 hrs p.i., copy numbers
of total viral DNA in infected cells were quantified by qPCR; the
levels of B19V VP2-encoding mRNA per b-actin mRNA in
infected cells were quantified. (B) HIF1a was detected in UT7/
Epo-S1 cells cultured under normoxia (N) or hypoxia (H) by
Western blotting. (C, D&E) UT7/Epo-S1 cells cultured under
normoxia were treated with CoCl2 at the final concentrations
indicated. CoCl2 (CX1800) was purchased from EMD Biochem-
icals, and dissolved in distilled H2O. At 24 hrs post-treatment, cells
were detected for HIF1a stabilization by Western blotting (C). The
cells also were transfected with a GFP reporter plasmid (pcDNA-
P6-GFP) (diagramed in panel D). At 48 hrs post-transfection, GFP
expression in the cells of each group was quantified as MFI using
flow cytometry. The MFI in the ‘‘0’’ group is arbitrarily set up as
1, and relative MFI is shown (E). (F) CoCl2 did not show any
cytotoxicity at a final concentration of 200 mM. UT7/Epo-S1 cells
were cultured under normoxia and treated with CoCl2 at
indicated concentrations. Cytotoxicity was evaluated by the
CellTiter-GloH kit at 48 hrs post-treatment.
(TIF)
Figure S2 HIF2a and HIF3a do not affect B19V infection
of CD36
+ EPCs cultured under hypoxia. Day 7 CD36
+
EPCs cultured under hypoxia were transduced with the indicated
lentivirus at 48 hrs prior to B19V infection (at an MOI of
2,000 gc/cell). At 48 hrs p.i., transduced cells were analyzed for
expression of B19V NS1, HIF2a and HIF3a by flow cytometry.
Percentages of NS1-positve cells are shown in the first column, and
numbers shown in the middle and right columns are MFIs of
HIF2a and HIF3a, respectively. Dashed reference lines are drawn
arbitrarily to show the relative position of the peaks. Bkg,
background, represents the second antibody control.
(TIF)
Figure S3 Proliferation, viability and cell cycle analysis
of CD36
+ EPCs cultured under normoxia vs. hypoxia. (A)
The total numbers of CD36
+ EPCs cultured under either
normoxia or hypoxia were counted on each day of culture using
hemocytometer and plotted to the days of culture. (B) Proliferation
of CD36
+ EPCs cultured under either normoxia or hypoxia was
determined using the CellTiter-GloH kit for intracellular ATP.
The value on day 4 is arbitrarily set up as 1, to which the relative
values are plotted to the days of culture. (C) The cell cycle was
analyzed by DAPI staining, and the percentages of each cell cycle
phase in the live cell population are shown on the top right corner
in each plot. The sub G0 population, as shown vertically to the left
of each panel, represents levels of cell death.
(TIF)
Figure S4 Cytotoxicity detection of the pharmacological
inhibitors and lentiviral vectors used in the study. (A)
CellTiter-GloH kit was used to determine viability of the cells at
48 hrs post-treatment with chemicals indicated. The final
concentrations of each inhibitor tested are shown. The highest
concentration of DMSO used to dissolve the inhibitors was 0.5%,
which was therefore used as a DMSO control. The value
determined from the cell only control group is arbitrarily set up
as 1, and relative viability is shown. (B) Day 7 CD36
+ EPCs
cultured under normoxia and hypoxia indicated were transduced
using respective shRNA-encoding lentivirus as shown. Flow
cytometry analysis was carried out at 48 hrs post-transduction to
determine the cell cycle status in each group. The percentage of
sub G0 was presented as an indicator of cell death. The percentage
of cells at G0/G1, S or G2/M phase was the relative value of non-
Sub G0 cells.
(TIF)
Figure S5 Phosphorylation of STAT5A and MEK does
not affect each other significantly. (A) Day 7 CD36
+ EPCs
cultured under normoxia were either transduced with MEK-
targeted shRNA (MEK shRNA) and scrambled shRNA, respec-
tively, or treated with MEK-specific inhibitor U0126 at a final
concentration of 10 mM. (B) Day 7 CD36
+ EPCs cultured under
normoxia were transduced with Lenti-GFP and Lenti-UTR-
STAT5A(1*6). At 48 hrs post-transduction or post-treatment, the
levels of pSTAT5A (A) and pERK1/2 (B) were analyzed by flow
cytometry. The GFP-positive population of lentivirus-transduced
cells was selectively gated. Numbers shown are MFI of the whole
peak. Dashed reference line is selected arbitrarily to show the
relative position of the peaks. Bkg, background, secondary
antibody only.
(TIF)
Figure S6 HIFa does not modulate phosphorylation of
STAT5A and MEK1/2 under normoxia and hypoxia. Day
7 CD36
+ EPCs cultured under either normoxia or hypoxia were
transduced by respective shRNA-encoding lentivirus. The levels of
phosphorylated ERK1/2 (pERK1/2) and phosphorylated
STAT5A (pSTAT5A) were determined by flow cytometry at
48 hrs post-transduction. The dash line was drawn arbitrarily to
show the shift of staining peak from the background control (Bkg).
The numbers in the plots of the left and right columns show MFI
values of pERK1/2 and pSTAT5A, respectively.
(TIF)
Table S1 Sequences of shRNAs used in this study.
(DOC)
Text S1 Supplemental methods.
(DOC)
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